昌红科技(300151) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 20,768,311.17, reflecting a growth of 2.57% year-on-year[8]. - Operating revenue for the period was CNY 184,790,052.80, a slight increase of 0.47% compared to the same period last year[8]. - The net profit after deducting non-recurring gains and losses was CNY 18,827,526.95, up by 6.24% year-on-year[8]. - Basic earnings per share were CNY 0.0413, representing a growth of 2.48% compared to the same period last year[8]. - The weighted average return on equity was 2.34%, a decrease of 0.03% from the previous year[8]. - Total operating revenue for the current period reached ¥184,790,052.80, a slight increase from ¥183,928,083.58 in the previous period, representing a growth of approximately 0.47%[66]. - Net profit for the current period was ¥20,546,101.06, compared to ¥19,958,864.94 in the previous period, reflecting an increase of approximately 2.94%[69]. - The total profit for the current period was ¥23,612,499.04, compared to ¥23,226,665.13 in the previous period, reflecting an increase of about 1.66%[69]. - Net profit for the current period was ¥50,640,776.71, representing an 18.5% increase from ¥42,865,722.37 in the previous period[89]. - The company’s total comprehensive income for the current period was ¥55,685,560.00, compared to ¥46,808,237.60 in the previous period, an increase of 18.5%[91]. Assets and Liabilities - Total assets reached CNY 1,067,056,189.48, an increase of 2.94% compared to the previous year-end[8]. - The company's total assets reached RMB 1,067,056,189.48 as of September 30, 2019, compared to RMB 1,036,561,045.79 at the end of 2018[49]. - Total liabilities increased to ¥151.81 billion, up from ¥145.72 billion, representing a growth of 4.7% year-over-year[52]. - Current liabilities totaled ¥147.34 billion, compared to ¥140.02 billion, reflecting an increase of 5.4%[52]. - Non-current liabilities decreased to ¥4.47 billion from ¥5.71 billion, a decline of 21.8%[52]. - Owner's equity rose to ¥915.25 billion, up from ¥890.84 billion, indicating a growth of 2.9%[55]. - Total current assets as of September 30, 2019, amounted to RMB 593,576,867.18, a decrease from RMB 654,085,630.07 at the end of 2018[49]. - The company reported a total equity attributable to shareholders of ¥875,001,060.41, with minority interests of ¥15,835,962.26[123]. Cash Flow - Cash flow from operating activities for the year-to-date was CNY 106,258,441.66, down by 2.66% year-on-year[8]. - The net cash flow from operating activities decreased to ¥63,417,210.35 from ¥84,389,025.60, representing a decline of approximately 25% year-over-year[110]. - Cash inflow from operating activities totaled 613,578,201.90, compared to 565,818,324.69 in the previous period[103]. - Cash outflow from operating activities was 507,319,760.24, up from 456,656,843.85 in the previous period[103]. - Investment activities generated a net cash outflow of -139,185,143.48, compared to -112,559,670.65 in the previous period[106]. Investments - The company made a long-term equity investment of $3,000,024 in Pneuma Respiratory, Inc., acquiring a 4.28% stake, to enhance its medical industry layout[29]. - The company established a medical industry merger fund with a total commitment of ¥20 million, aimed at investing in the pharmaceutical sector[30]. - Long-term equity investments surged by 246.41% to ¥31,510,944.82, reflecting significant investment activities[24]. - The company reported an investment income of ¥6,584,776.89, significantly higher than ¥3,136,907.89 from the previous period, showing an increase of 110.4%[86]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,327[12]. - The largest shareholder, Li Huanchang, holds 42.19% of the shares, totaling 211,995,500 shares[12]. - The company distributed cash dividends of RMB 0.600215 per 10 shares, totaling RMB 30,149,999.87, executed on June 12, 2019[39]. - The company paid out ¥30,149,999.87 in dividends, up from ¥15,075,000.00, indicating a 100% increase in dividend distribution[110]. Expenses - The company reported a 19.63% increase in sales expenses, totaling ¥17,120,837.99, attributed to higher shipping and promotional costs[27]. - The company’s financial expenses decreased by 28.16% to -¥7,425,731.86, mainly due to lower interest income from bank deposits[27]. - Research and development expenses decreased to ¥7,540,444.89 from ¥9,860,946.56, a reduction of about 23.5%[66]. - Research and development expenses decreased to ¥23,088,246.30 from ¥24,358,705.59, a reduction of 5.2%[86].